-
1
-
-
0032988610
-
Mild cognitive impairment: Clinical characterization and outcome
-
Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG and Kokmen E. Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 56: 303-308 (1999). (Pubitemid 29120227)
-
(1999)
Archives of Neurology
, vol.56
, Issue.3
, pp. 303-308
-
-
Petersen, R.C.1
Smith, G.E.2
Waring, S.C.3
Ivnik, R.J.4
Tangalos, E.G.5
Kokmen, E.6
-
2
-
-
0021207461
-
Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein
-
Glenner GG and Wong CW. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 122(3): 1131-1135 (1984).
-
(1984)
Biochem Biophys Res Commun
, vol.122
, Issue.3
, pp. 1131-1135
-
-
Glenner, G.G.1
Wong, C.W.2
-
3
-
-
0026745610
-
Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production
-
DOI 10.1038/360672a0
-
Citron M, Oltersdorf T, Haas C, McConlogue L, Hung AY, Seubert P, et al. Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production. Nature 360: 672-674 (1992). (Pubitemid 23007680)
-
(1992)
Nature
, vol.360
, Issue.6405
, pp. 672-674
-
-
Citron, M.1
Oltersdorf, T.2
Haass, C.3
McConlogue, L.4
Hung, A.Y.5
Seubert, P.6
Vigo-Pelfrey, C.7
Lieberburg, I.8
Selkoe, D.J.9
-
4
-
-
0028322017
-
717) mutants
-
Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L Jr, Eckman C, et al. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP 717) mutants. Science 264: 1336-1340 (1994). (Pubitemid 24219086)
-
(1994)
Science
, vol.264
, Issue.5163
, pp. 1336-1340
-
-
Suzuki, N.1
Cheung, T.T.2
Cai, X.-D.3
Odaka, A.4
Otvos Jr., L.5
Eckman, C.6
Golde, T.E.7
Younkin, S.G.8
-
5
-
-
16044373524
-
Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
-
Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2: 864-870 (1996).
-
(1996)
Nat Med
, vol.2
, pp. 864-870
-
-
Scheuner, D.1
Eckman, C.2
Jensen, M.3
Song, X.4
Citron, M.5
Suzuki, N.6
-
6
-
-
0042838303
-
Alzheimer's disease-affected brain: Presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss
-
DOI 10.1073/pnas.1834302100
-
Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, et al. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggest a molecular basis for reversible memory loss. Proc Natl Acad Sci USA 100 (18): 10417-10422 (2003). (Pubitemid 37071893)
-
(2003)
Proceedings of the National Academy of Sciences of the United States of America
, vol.100
, Issue.18
, pp. 10417-10422
-
-
Gong, Y.1
Chang, L.2
Viola, K.L.3
Lacor, P.N.4
Lambert, M.P.5
Finch, C.E.6
Krafft, G.A.7
Klein, W.L.8
-
8
-
-
14644416500
-
Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions
-
Bennett DA, Schneider JA, Bienias JL, Evans DA and Wilson RS. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology 64: 834-841 (2005).
-
(2005)
Neurology
, vol.64
, pp. 834-841
-
-
Bennett, D.A.1
Schneider, J.A.2
Bienias, J.L.3
Evans, D.A.4
Wilson, R.S.5
-
9
-
-
4544335597
-
Mild cognitive impairment as a diagnostic entity
-
Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 256: 182-194 (2004).
-
(2004)
J Intern Med
, vol.256
, pp. 182-194
-
-
Petersen, R.C.1
-
10
-
-
22844444303
-
Mild cognitive impairment as a clinical entity and treatment target
-
Petersen RC and Morris JC. Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol 62: 1160-1163 (2005).
-
(2005)
Arch Neurol
, vol.62
, pp. 1160-1163
-
-
Petersen, R.C.1
Morris, J.C.2
-
11
-
-
0035826771
-
Practice parameter: Management of dementia (an evidence-based review): Report of the quality standards subcommittee of the American Academy of Neurology
-
Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, et al. Practice parameter: management of dementia (an evidencebased review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56: 1154-1166 (2001). (Pubitemid 32405709)
-
(2001)
Neurology
, vol.56
, Issue.9
, pp. 1154-1166
-
-
Doody, R.S.1
Stevens, J.C.2
Beck, C.3
Dubinsky, R.M.4
Kaye, J.A.5
Gwyther, L.6
Mohs, R.C.7
Thal, L.J.8
Whitehouse, P.J.9
Dekosky, S.T.10
Cummings, J.L.11
-
12
-
-
4143052423
-
Efficacy of donepezil in mild cognitive impairment
-
Salloway S, Ferris S, Kluger A, Goldman R, Griesing T, Kumar D, et al. Efficacy of donepezil in mild cognitive impairment. Neurology 63: 651-657 (2004).
-
(2004)
Neurology
, vol.63
, pp. 651-657
-
-
Salloway, S.1
Ferris, S.2
Kluger, A.3
Goldman, R.4
Griesing, T.5
Kumar, D.6
-
13
-
-
0030862602
-
Validity and reliability of the Alzheimer's disease cooperative study-clinical global impression of change
-
Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 11(2): S22-S32 (1997). (Pubitemid 27303107)
-
(1997)
Alzheimer Disease and Associated Disorders
, vol.11
, Issue.SUPPL. 2
-
-
Schneider, L.S.1
Olin, J.T.2
Doody, R.S.3
Clark, C.M.4
Morris, J.C.5
Reisberg, B.6
Schmitt, F.A.7
Grundman, M.8
Thomas, R.G.9
Ferris, S.H.10
-
14
-
-
0033380443
-
Neuropsychological prediction of decline to dementia in nondemented elderly
-
Kluger A, Ferris SH, Golumb J, Mittelman MS and Reisberg B. Neuropsychological prediction of decline to dementia in non demented elderly. J Geriatr Psychiatry Neurol 12: 168-179 (1999). (Pubitemid 30072300)
-
(1999)
Journal of Geriatric Psychiatry and Neurology
, vol.12
, Issue.4
, pp. 168-179
-
-
Kluger, A.1
Ferris, S.H.2
Golomb, J.3
Mittelman, M.S.4
Reisberg, B.5
-
15
-
-
0030470196
-
The Alzheimer's Disease Assessment Scale
-
Mohs RC. The Alzheimer's Disease Assessment Scale. Int Psychogeriatr 8: 195-203 (1996).
-
(1996)
Int Psychogeriatr
, vol.8
, pp. 195-203
-
-
Mohs, R.C.1
-
18
-
-
4644312295
-
B receptor antagonist in clinical trials
-
DOI 10.1016/j.bcp.2004.07.030, PII S0006295204005441, Six Decades of GABA
-
Froestl W, Gallagher M, Jenkins H, Madrid A, Melcher T, Teichman S, et al. SGS742: the first GABA(B) receptor antagonist in clinical trials. Biochem Pharmacol 68(8): 1479-1487 (2004). (Pubitemid 39286451)
-
(2004)
Biochemical Pharmacology
, vol.68
, Issue.8
, pp. 1479-1487
-
-
Froestl, W.1
Gallagher, M.2
Jenkins, H.3
Madrid, A.4
Melcher, T.5
Teichman, S.6
Mondadori, C.G.7
Pearlman, R.8
-
19
-
-
0025890255
-
The Hopkins verbal learning test: Development of a new memory test with six equivalent forms
-
Brandt J. The Hopkins verbal learning test: Development of a new memory test with six equivalent forms. Clin Neurophychol 5: 125-142 (1991).
-
(1991)
Clin Neurophychol
, vol.5
, pp. 125-142
-
-
Brandt, J.1
-
20
-
-
33645558594
-
Clinical trials in mild cognitive impairment. lessons for the future
-
Jelic V, Kivipelto M, Winblad B. Clinical trials in mild cognitive impairment. lessons for the future. J Neurol Neurosurg Psychiatry 77: 429-438 (2006).
-
(2006)
J Neurol Neurosurg Psychiatry
, vol.77
, pp. 429-438
-
-
Jelic, V.1
Kivipelto, M.2
Winblad, B.3
-
21
-
-
69149101850
-
-
http://clinicaltrials.gov/
-
-
-
-
22
-
-
20344381835
-
Vitamin e and donepezil for the treatment of mild cognitive impairment
-
DOI 10.1056/NEJMoa050151
-
Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352: 2379-2388 (2005). (Pubitemid 40958434)
-
(2005)
New England Journal of Medicine
, vol.352
, Issue.23
, pp. 2379-2388
-
-
Petersen, R.C.1
Thomas, R.G.2
Grundman, M.3
Bennett, D.4
Doody, R.5
Ferris, S.6
Galasko, D.7
Jin, S.8
Kaye, J.9
Levey, A.10
Pfeiffer, E.11
Sano, M.12
Van Dyck, C.H.13
Thal, L.J.14
-
23
-
-
0030967165
-
A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease
-
DOI 10.1056/NEJM199704243361704
-
Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 336: 1216-1222 (1997). (Pubitemid 27183651)
-
(1997)
New England Journal of Medicine
, vol.336
, Issue.17
, pp. 1216-1222
-
-
Sano, M.1
Ernesto, C.2
Thomas, R.G.3
Klauber, M.R.4
Schafer, K.5
Grundman, M.6
Woodbury, P.7
Growdon, J.8
Cotman, C.W.9
Pfeiffer, E.10
Schneider, L.S.11
Thal, L.J.12
-
24
-
-
34248175274
-
Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment
-
DOI 10.1212/01.wnl.0000258542.58725.4c
-
Fleisher AS, Sowell BB, Taylor C, Gamst AC, Petersen RC and Thal LJ. Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology 68: 1588-1595 (2007). (Pubitemid 46717983)
-
(2007)
Neurology
, vol.68
, Issue.19
, pp. 1588-1595
-
-
Fleisher, A.S.1
Sowell, B.B.2
Taylor, C.3
Gamst, A.C.4
Petersen, R.C.5
Thal, L.J.6
-
25
-
-
33644791818
-
Impact of APOE genotype on the efficacy of galantamine for the treatment of mild cognitive impairment
-
Gold M, Francke S, Nye JS, Goldstein HR, Fijal B, Truyen L, et al. Impact of APOE genotype on the efficacy of galantamine for the treatment of mild cognitive impairment. Neurobiol Aging 25(2): S521 (2004).
-
(2004)
Neurobiol Aging
, vol.25
, Issue.2
-
-
Gold, M.1
Francke, S.2
Nye, J.S.3
Goldstein, H.R.4
Fijal, B.5
Truyen, L.6
-
26
-
-
33645571173
-
Galantamine in the treatment of patients with mild cognitive impairment: Baseline demographics and psychometric testing results
-
Goldstein HR and Gold M. Galantamine in the treatment of patients with mild cognitive impairment: baseline demographics and psychometric testing results. Neurobiol Aging 25(2): S472-473 (2004).
-
(2004)
Neurobiol Aging
, vol.25
, Issue.2
-
-
Goldstein, H.R.1
Gold, M.2
-
27
-
-
33645433543
-
Galantamine in the treatment of patients with mild cognitive impairment: Effect of diagnostic type at baseline
-
Novak G. Galantamine in the treatment of patients with mild cognitive impairment: effect of diagnostic type at baseline. Neurobiol Aging 25(2): S474 (2004).
-
(2004)
Neurobiol Aging
, vol.25
, Issue.2
-
-
Novak, G.1
-
28
-
-
11144246343
-
Effect of galantamine on brain atrophy as assessed by MRI in patients with mild cognitive impairment
-
Scheltens P, Fox NC, Barkhof F and Gold M. Effect of galantamine on brain atrophy as assessed by MRI in patients with mild cognitive impairment. Neurobiol Aging 25 : S270-271 (2004).
-
(2004)
Neurobiol Aging
, vol.25
-
-
Scheltens, P.1
Fox, N.C.2
Barkhof, F.3
Gold, M.4
-
29
-
-
0027425211
-
The clinical dementia rating (CDR): Current version and scoring rules
-
Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology 43: 2412-2414 (1993).
-
(1993)
Neurology
, vol.43
, pp. 2412-2414
-
-
Morris, J.C.1
-
30
-
-
0030771116
-
An inventory to assess activities of daily living for clinical trials in Alzheimer's disease
-
Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimer Dis Assoc Disord 11(2): S33-S39 (1997). (Pubitemid 27303108)
-
(1997)
Alzheimer Disease and Associated Disorders
, vol.11
, Issue.SUPPL. 2
-
-
Galasko, D.1
Bennett, D.2
Sano, M.3
Ernesto, C.4
Thomas, R.5
Grundman, M.6
Ferris, S.7
-
31
-
-
34248372938
-
Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: The InDDEx study
-
DOI 10.1016/S1474-4422(07)70109-6, PII S1474442207701096
-
Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDex study. Lancet Neurol 6(6): 501-512 (2007). (Pubitemid 46738627)
-
(2007)
Lancet Neurology
, vol.6
, Issue.6
, pp. 501-512
-
-
Feldman, H.H.1
Ferris, S.2
Winblad, B.3
Sfikas, N.4
Mancione, L.5
He, Y.6
Tekin, S.7
Burns, A.8
Cummings, J.9
Del Ser, T.10
Inzitari, D.11
Orgogozo, J.-M.12
Sauer, H.13
Scheltens, P.14
Scarpini, E.15
Herrmann, N.16
Farlow, M.17
Potkin, S.18
Charles, H.C.19
Fox, N.C.20
Lane, R.21
more..
-
32
-
-
0015812367
-
Selective reminding for analysis of memory and learning
-
Buschke H. Selective reminding for analysis of memory and learning. J Verbal Learn Verbal Behav 12: 543-550 (1973).
-
(1973)
J Verbal Learn Verbal Behav
, vol.12
, pp. 543-550
-
-
Buschke, H.1
-
33
-
-
8844273984
-
Impact of APOE in mild cognitive impairment
-
Farlow MR, He Y, Tekin S, Xu J, Lane R and Charles HC. Impact of APOE in mild cognitive impairment. Neurology 63: 1898-1901 (2004).
-
(2004)
Neurology
, vol.63
, pp. 1898-1901
-
-
Farlow, M.R.1
He, Y.2
Tekin, S.3
Xu, J.4
Lane, R.5
Charles, H.C.6
-
34
-
-
21144447586
-
A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment
-
DOI 10.1038/sj.npp.1300690
-
Thal LJ, Ferris SH, Kirby L, Block GA, Lines RC, Yuen E, et al. A randomized double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 30(6); 1204-1215 (2005). (Pubitemid 40720980)
-
(2005)
Neuropsychopharmacology
, vol.30
, Issue.6
, pp. 1204-1215
-
-
Thal, L.J.1
Ferris, S.H.2
Kirby, L.3
Block, G.A.4
Lines, C.R.5
Yuen, E.6
Assaid, C.7
Nessly, M.L.8
Norman, B.A.9
Baranak, C.C.10
Reines, S.A.11
-
35
-
-
69149089566
-
Longitudinal PIB measures in control, MCI and AD subjects
-
Mathis C, Price J, Klunk W, Weissfield L, McNamee R, Wolk D, et al. Longitudinal PIB measures in control, MCI and AD subjects. J Nucl Med 49(1); 35P (2008).
-
(2008)
J Nucl Med
, vol.49
, Issue.1
-
-
Mathis, C.1
Price, J.2
Klunk, W.3
Weissfield, L.4
McNamee, R.5
Wolk, D.6
-
36
-
-
69149095505
-
Use of biomarker covariants to increase power
-
Oral Presentation at the
-
Donohue M and Beckett L. Use of biomarker covariants to increase power. Oral Presentation at the International Conference on Alzheimer Disease, Chicago, IL, USA, July (2008).
-
International Conference on Alzheimer Disease, Chicago, IL, USA, July (2008)
-
-
Donohue, M.1
Beckett, L.2
-
37
-
-
68849102065
-
Treatment response to rivastigmine in mild cognitive impairment: An enhanced statistical modeling approach
-
Submitted
-
Ferris S, Lane R, Sfikas N, Winblad B, Farlow M and Feldman HH. Treatment response to rivastigmine in mild cognitive impairment: An enhanced statistical modeling approach. Gend Med. Submitted (2009).
-
(2009)
Gend Med
-
-
Ferris, S.1
Lane, R.2
Sfikas, N.3
Winblad, B.4
Farlow, M.5
Feldman, H.H.6
|